Anna C. Pavlick
Cornell University(US)Weill Cornell Medicine(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma(2015)2,746 cited
- → Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib(2012)2,141 cited
- → Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial(2015)1,554 cited
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,298 cited
- → Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial(2016)972 cited
- → Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial(2012)929 cited